May 30, 2018 05:43 PM EDT
R&D
Pharma

Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

Brittany Meiling

San Fran’s I/O dar­ling Nek­tar Ther­a­peu­tics $NK­TR is hand­ing off ac­cess to its pop­u­lar can­cer can­di­date NK­TR-214 to see how the ther­a­py fairs when paired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times